Adriana Weinberg
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 98 | 2026 | 2970 | 10.020 |
Why?
| | Herpes Zoster Vaccine | 25 | 2025 | 160 | 9.890 |
Why?
| | Herpes Zoster | 33 | 2025 | 319 | 9.320 |
Why?
| | Herpesvirus 3, Human | 37 | 2025 | 336 | 7.460 |
Why?
| | Cytomegalovirus Infections | 28 | 2024 | 197 | 6.050 |
Why?
| | Influenza Vaccines | 29 | 2021 | 551 | 5.860 |
Why?
| | Immunity, Cellular | 34 | 2025 | 267 | 5.720 |
Why?
| | Antibodies, Viral | 44 | 2024 | 654 | 5.380 |
Why?
| | T-Lymphocytes, Regulatory | 15 | 2025 | 393 | 4.760 |
Why?
| | Pregnancy Complications, Infectious | 25 | 2026 | 407 | 4.420 |
Why?
| | Cytomegalovirus | 27 | 2024 | 163 | 4.350 |
Why?
| | Influenza, Human | 27 | 2021 | 631 | 3.950 |
Why?
| | Antiretroviral Therapy, Highly Active | 22 | 2017 | 278 | 2.860 |
Why?
| | Anti-HIV Agents | 19 | 2026 | 846 | 2.600 |
Why?
| | Influenza A Virus, H1N1 Subtype | 13 | 2021 | 153 | 2.580 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2025 | 77 | 2.570 |
Why?
| | Vaccines, Attenuated | 23 | 2024 | 130 | 2.550 |
Why?
| | Pneumococcal Infections | 4 | 2022 | 108 | 2.540 |
Why?
| | T-Lymphocyte Subsets | 12 | 2019 | 414 | 2.500 |
Why?
| | Immunologic Memory | 14 | 2020 | 359 | 2.430 |
Why?
| | T-Lymphocytes | 22 | 2020 | 2006 | 2.420 |
Why?
| | Leukocytes, Mononuclear | 16 | 2025 | 572 | 2.310 |
Why?
| | CD4-Positive T-Lymphocytes | 29 | 2023 | 1113 | 2.130 |
Why?
| | Respiratory Tract Infections | 7 | 2025 | 386 | 2.100 |
Why?
| | Vaccination | 23 | 2024 | 1468 | 1.650 |
Why?
| | Chickenpox | 8 | 2024 | 81 | 1.640 |
Why?
| | Antiviral Agents | 17 | 2023 | 747 | 1.580 |
Why?
| | Humans | 237 | 2026 | 141265 | 1.580 |
Why?
| | Chickenpox Vaccine | 11 | 2024 | 74 | 1.570 |
Why?
| | Interferon-gamma | 20 | 2022 | 789 | 1.560 |
Why?
| | Drug Resistance, Viral | 14 | 2017 | 120 | 1.450 |
Why?
| | HIV | 8 | 2022 | 248 | 1.440 |
Why?
| | Female | 163 | 2026 | 75727 | 1.440 |
Why?
| | Virus Diseases | 4 | 2018 | 215 | 1.360 |
Why?
| | CD8-Positive T-Lymphocytes | 12 | 2019 | 916 | 1.360 |
Why?
| | DNA, Viral | 13 | 2024 | 363 | 1.330 |
Why?
| | Tetanus Toxoid | 4 | 2021 | 37 | 1.310 |
Why?
| | Pregnancy | 43 | 2026 | 7039 | 1.300 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 1.280 |
Why?
| | Infectious Disease Transmission, Vertical | 10 | 2023 | 186 | 1.260 |
Why?
| | Infant | 42 | 2025 | 9801 | 1.230 |
Why?
| | Influenza A virus | 9 | 2013 | 110 | 1.200 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 9 | 2009 | 28 | 1.200 |
Why?
| | Influenza B virus | 9 | 2017 | 44 | 1.190 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 131 | 1.170 |
Why?
| | Hepatitis A Vaccines | 5 | 2020 | 15 | 1.160 |
Why?
| | Antibodies, Bacterial | 5 | 2022 | 145 | 1.140 |
Why?
| | Adult | 99 | 2026 | 39201 | 1.130 |
Why?
| | Vaccines, Synthetic | 7 | 2025 | 138 | 1.130 |
Why?
| | Dermatitis, Atopic | 5 | 2020 | 331 | 1.110 |
Why?
| | B-Lymphocytes | 7 | 2021 | 858 | 1.100 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2023 | 101 | 1.090 |
Why?
| | Adjuvants, Immunologic | 8 | 2021 | 238 | 1.080 |
Why?
| | Male | 124 | 2025 | 70061 | 1.080 |
Why?
| | HIV-1 | 13 | 2019 | 880 | 1.030 |
Why?
| | CD4 Lymphocyte Count | 17 | 2019 | 273 | 1.030 |
Why?
| | Antibody Formation | 7 | 2023 | 297 | 1.010 |
Why?
| | Hemagglutination Inhibition Tests | 14 | 2021 | 38 | 1.000 |
Why?
| | Anti-Retroviral Agents | 8 | 2023 | 240 | 0.980 |
Why?
| | Pneumococcal Vaccines | 3 | 2022 | 138 | 0.970 |
Why?
| | Lymphocyte Activation | 26 | 2020 | 1142 | 0.960 |
Why?
| | Transforming Growth Factor beta | 4 | 2025 | 498 | 0.960 |
Why?
| | Gastrointestinal Microbiome | 2 | 2025 | 723 | 0.950 |
Why?
| | Breast Feeding | 4 | 2023 | 442 | 0.940 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2025 | 171 | 0.930 |
Why?
| | Interleukin-2 | 13 | 2022 | 451 | 0.910 |
Why?
| | Vaccines, Inactivated | 10 | 2017 | 68 | 0.890 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.890 |
Why?
| | Monocytes | 2 | 2025 | 578 | 0.880 |
Why?
| | Enzyme-Linked Immunospot Assay | 6 | 2018 | 37 | 0.880 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 670 | 0.880 |
Why?
| | Viral Load | 18 | 2023 | 501 | 0.880 |
Why?
| | Viremia | 9 | 2021 | 149 | 0.870 |
Why?
| | Infant, Newborn | 24 | 2025 | 6262 | 0.860 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 67 | 0.830 |
Why?
| | Child, Preschool | 35 | 2025 | 11473 | 0.820 |
Why?
| | Isoniazid | 6 | 2026 | 61 | 0.820 |
Why?
| | Immune Reconstitution | 1 | 2023 | 8 | 0.810 |
Why?
| | Child | 54 | 2025 | 22342 | 0.810 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2013 | 98 | 0.810 |
Why?
| | Tuberculosis | 6 | 2026 | 279 | 0.790 |
Why?
| | Environmental Exposure | 2 | 2018 | 578 | 0.770 |
Why?
| | Papillomavirus Vaccines | 3 | 2018 | 317 | 0.750 |
Why?
| | Herpesvirus 1, Human | 3 | 2016 | 80 | 0.740 |
Why?
| | Receptors, Tumor Necrosis Factor | 8 | 2001 | 166 | 0.730 |
Why?
| | Double-Blind Method | 17 | 2021 | 1980 | 0.730 |
Why?
| | Adolescent | 54 | 2025 | 22064 | 0.720 |
Why?
| | Cytokines | 12 | 2025 | 2093 | 0.720 |
Why?
| | Young Adult | 30 | 2026 | 13665 | 0.700 |
Why?
| | Middle Aged | 63 | 2024 | 34595 | 0.700 |
Why?
| | Orthomyxoviridae | 3 | 2017 | 40 | 0.700 |
Why?
| | Polymerase Chain Reaction | 12 | 2023 | 1052 | 0.690 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 68 | 0.670 |
Why?
| | Aged | 42 | 2024 | 24796 | 0.670 |
Why?
| | DNA-Directed DNA Polymerase | 4 | 2008 | 48 | 0.660 |
Why?
| | Vitamin D | 2 | 2024 | 392 | 0.650 |
Why?
| | Aged, 80 and over | 18 | 2022 | 7947 | 0.650 |
Why?
| | Rotavirus Infections | 2 | 2017 | 39 | 0.640 |
Why?
| | Herpesvirus 4, Human | 8 | 2014 | 165 | 0.640 |
Why?
| | Viral Proteins | 5 | 2012 | 369 | 0.640 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 42 | 0.630 |
Why?
| | Immunosuppressive Agents | 7 | 2014 | 855 | 0.620 |
Why?
| | Viral Envelope Proteins | 2 | 2021 | 97 | 0.600 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2016 | 37 | 0.590 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2019 | 38 | 0.590 |
Why?
| | Antibodies, Neutralizing | 7 | 2021 | 321 | 0.590 |
Why?
| | RNA, Viral | 9 | 2024 | 694 | 0.580 |
Why?
| | Paramyxoviridae Infections | 2 | 2011 | 12 | 0.570 |
Why?
| | Simplexvirus | 9 | 2016 | 82 | 0.570 |
Why?
| | Human papillomavirus 18 | 1 | 2018 | 14 | 0.570 |
Why?
| | Mycobacterium tuberculosis | 1 | 2021 | 316 | 0.560 |
Why?
| | Human papillomavirus 16 | 1 | 2018 | 31 | 0.560 |
Why?
| | Immunocompromised Host | 9 | 2019 | 201 | 0.560 |
Why?
| | Hepatitis A Antibodies | 2 | 2009 | 3 | 0.560 |
Why?
| | Cryopreservation | 2 | 2010 | 105 | 0.560 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2019 | 126 | 0.550 |
Why?
| | Th1 Cells | 1 | 2018 | 139 | 0.540 |
Why?
| | Antitubercular Agents | 4 | 2026 | 200 | 0.540 |
Why?
| | Lymphocyte Subsets | 2 | 2015 | 88 | 0.530 |
Why?
| | Antigens, Viral | 8 | 2017 | 179 | 0.530 |
Why?
| | Immunoconjugates | 2 | 2013 | 127 | 0.520 |
Why?
| | Flow Cytometry | 11 | 2019 | 1196 | 0.520 |
Why?
| | Hospitalization | 6 | 2021 | 2270 | 0.520 |
Why?
| | Immunization, Secondary | 6 | 2017 | 92 | 0.520 |
Why?
| | Age Factors | 9 | 2019 | 3292 | 0.520 |
Why?
| | Mutation | 7 | 2009 | 4009 | 0.510 |
Why?
| | Acyclovir | 6 | 2012 | 95 | 0.500 |
Why?
| | Herpesviridae Infections | 5 | 2013 | 148 | 0.500 |
Why?
| | Premature Birth | 2 | 2019 | 363 | 0.490 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 1999 | 68 | 0.490 |
Why?
| | Case-Control Studies | 14 | 2024 | 3580 | 0.490 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 370 | 0.480 |
Why?
| | Viral Vaccines | 4 | 2014 | 107 | 0.470 |
Why?
| | Herpes Simplex | 4 | 2016 | 94 | 0.470 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2011 | 173 | 0.470 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2005 | 35 | 0.460 |
Why?
| | Contraceptive Agents, Female | 1 | 2016 | 79 | 0.450 |
Why?
| | Central Nervous System Viral Diseases | 3 | 2004 | 77 | 0.450 |
Why?
| | Postpartum Period | 6 | 2026 | 343 | 0.440 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 78 | 0.440 |
Why?
| | Immunoglobulin G | 7 | 2021 | 899 | 0.430 |
Why?
| | Immunoassay | 5 | 2017 | 113 | 0.430 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 96 | 0.430 |
Why?
| | Killer Cells, Natural | 4 | 2025 | 467 | 0.430 |
Why?
| | Injections, Intramuscular | 4 | 2017 | 135 | 0.430 |
Why?
| | Foscarnet | 6 | 2008 | 20 | 0.420 |
Why?
| | Immunophenotyping | 6 | 2019 | 327 | 0.410 |
Why?
| | Transplant Recipients | 3 | 2024 | 181 | 0.400 |
Why?
| | Antigen-Presenting Cells | 4 | 2022 | 159 | 0.400 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1769 | 0.400 |
Why?
| | B-Lymphocytes, Regulatory | 1 | 2013 | 3 | 0.400 |
Why?
| | CD4 Antigens | 2 | 2011 | 141 | 0.390 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2020 | 46 | 0.390 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 436 | 0.390 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2020 | 86 | 0.380 |
Why?
| | Immune Tolerance | 2 | 2013 | 374 | 0.380 |
Why?
| | Alphapapillomavirus | 1 | 2012 | 38 | 0.380 |
Why?
| | Hepatitis A | 1 | 2012 | 26 | 0.370 |
Why?
| | Candida | 3 | 2010 | 41 | 0.370 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 63 | 0.370 |
Why?
| | Cell Proliferation | 6 | 2020 | 2504 | 0.370 |
Why?
| | Cohort Studies | 11 | 2023 | 5802 | 0.370 |
Why?
| | Placebos | 5 | 2017 | 195 | 0.360 |
Why?
| | Polysaccharides | 2 | 2022 | 88 | 0.360 |
Why?
| | Skin | 1 | 2017 | 764 | 0.360 |
Why?
| | CD28 Antigens | 3 | 2009 | 58 | 0.360 |
Why?
| | Immunity, Innate | 2 | 2025 | 852 | 0.360 |
Why?
| | Metapneumovirus | 1 | 2011 | 15 | 0.350 |
Why?
| | Contraceptive Agents | 1 | 2012 | 66 | 0.350 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.350 |
Why?
| | Herpesvirus 2, Human | 2 | 2012 | 28 | 0.350 |
Why?
| | Lymphocyte Count | 4 | 2019 | 167 | 0.350 |
Why?
| | Lymphoproliferative Disorders | 1 | 2011 | 60 | 0.340 |
Why?
| | Benzoxazines | 4 | 2026 | 32 | 0.340 |
Why?
| | T-Lymphocytes, Helper-Inducer | 7 | 1994 | 136 | 0.340 |
Why?
| | Retrospective Studies | 21 | 2024 | 16373 | 0.340 |
Why?
| | Pregnancy Outcome | 7 | 2021 | 453 | 0.340 |
Why?
| | Blood | 2 | 2009 | 113 | 0.340 |
Why?
| | Nucleosides | 1 | 2010 | 26 | 0.340 |
Why?
| | Drug Therapy, Combination | 6 | 2019 | 1042 | 0.330 |
Why?
| | Streptococcus pneumoniae | 2 | 2022 | 167 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 260 | 0.320 |
Why?
| | Immunoglobulin A | 4 | 2017 | 215 | 0.320 |
Why?
| | Cytosine | 3 | 2008 | 48 | 0.320 |
Why?
| | Adaptive Immunity | 2 | 2017 | 172 | 0.320 |
Why?
| | Glycoproteins | 2 | 2023 | 358 | 0.320 |
Why?
| | Nucleotides | 1 | 2010 | 127 | 0.310 |
Why?
| | Antidepressive Agents | 3 | 2021 | 243 | 0.310 |
Why?
| | Refrigeration | 1 | 2009 | 12 | 0.310 |
Why?
| | Membrane Glycoproteins | 4 | 2001 | 501 | 0.310 |
Why?
| | Immunity, Humoral | 2 | 2021 | 116 | 0.310 |
Why?
| | Follow-Up Studies | 16 | 2024 | 5213 | 0.310 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 855 | 0.310 |
Why?
| | Organophosphonates | 3 | 2008 | 97 | 0.300 |
Why?
| | Astrocytes | 1 | 2011 | 216 | 0.300 |
Why?
| | Freezing | 1 | 2009 | 88 | 0.300 |
Why?
| | Coculture Techniques | 2 | 2025 | 244 | 0.300 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 21 | 0.290 |
Why?
| | Cyclopropanes | 4 | 2026 | 75 | 0.290 |
Why?
| | Tetanus | 2 | 2009 | 27 | 0.290 |
Why?
| | Alkynes | 4 | 2026 | 64 | 0.290 |
Why?
| | Lopinavir | 3 | 2023 | 28 | 0.280 |
Why?
| | Interleukin-10 | 3 | 2022 | 306 | 0.280 |
Why?
| | Time Factors | 18 | 2017 | 6971 | 0.280 |
Why?
| | Herpesvirus 7, Human | 2 | 2005 | 6 | 0.280 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 34 | 0.280 |
Why?
| | Prospective Studies | 14 | 2024 | 7787 | 0.280 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 101 | 0.280 |
Why?
| | Herpesvirus 6, Human | 2 | 2005 | 14 | 0.270 |
Why?
| | Longitudinal Studies | 8 | 2019 | 2923 | 0.270 |
Why?
| | Specimen Handling | 1 | 2009 | 180 | 0.270 |
Why?
| | Glioblastoma | 1 | 2011 | 344 | 0.270 |
Why?
| | Norgestrel | 1 | 2007 | 2 | 0.270 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 985 | 0.270 |
Why?
| | Interleukins | 2 | 2008 | 250 | 0.270 |
Why?
| | Biomarkers | 7 | 2021 | 4179 | 0.250 |
Why?
| | Apoptosis | 6 | 2011 | 2575 | 0.250 |
Why?
| | Incidence | 9 | 2023 | 2800 | 0.250 |
Why?
| | Nucleic Acid Hybridization | 2 | 2006 | 189 | 0.250 |
Why?
| | Antigens, CD | 5 | 2017 | 544 | 0.250 |
Why?
| | Lung Transplantation | 4 | 2002 | 323 | 0.240 |
Why?
| | Coinfection | 2 | 2019 | 131 | 0.240 |
Why?
| | Acetates | 2 | 2023 | 82 | 0.230 |
Why?
| | Fibroblasts | 4 | 2025 | 1019 | 0.230 |
Why?
| | Lymphokines | 5 | 1994 | 132 | 0.230 |
Why?
| | Bone Marrow Transplantation | 2 | 2005 | 295 | 0.230 |
Why?
| | Ritonavir | 2 | 2016 | 72 | 0.230 |
Why?
| | A549 Cells | 1 | 2025 | 74 | 0.220 |
Why?
| | Receptors, OX40 | 8 | 2001 | 15 | 0.220 |
Why?
| | Dexamethasone | 1 | 2007 | 379 | 0.220 |
Why?
| | Cell Survival | 5 | 2010 | 1131 | 0.220 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 8 | 0.220 |
Why?
| | Paramyxoviridae | 1 | 2004 | 2 | 0.220 |
Why?
| | Measles Vaccine | 1 | 2024 | 21 | 0.220 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2026 | 138 | 0.220 |
Why?
| | Virus Replication | 5 | 2017 | 532 | 0.210 |
Why?
| | Quinazolines | 2 | 2023 | 259 | 0.210 |
Why?
| | RNA, Messenger | 10 | 2011 | 2826 | 0.210 |
Why?
| | BCG Vaccine | 2 | 2023 | 24 | 0.210 |
Why?
| | Forkhead Transcription Factors | 3 | 2011 | 200 | 0.210 |
Why?
| | Ganciclovir | 4 | 2008 | 53 | 0.210 |
Why?
| | Milk, Human | 2 | 2023 | 169 | 0.210 |
Why?
| | Autoimmune Diseases | 3 | 2014 | 465 | 0.210 |
Why?
| | Immunity | 2 | 2020 | 139 | 0.210 |
Why?
| | Brazil | 2 | 2021 | 169 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 251 | 0.200 |
Why?
| | Estradiol | 1 | 2007 | 523 | 0.200 |
Why?
| | Cholecalciferol | 1 | 2024 | 61 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 1 | 2004 | 66 | 0.200 |
Why?
| | Myelin Basic Protein | 4 | 1998 | 44 | 0.200 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2023 | 29 | 0.200 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2023 | 232 | 0.200 |
Why?
| | Maternal-Fetal Exchange | 2 | 2016 | 170 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 639 | 0.200 |
Why?
| | Long-Term Care | 1 | 2024 | 110 | 0.200 |
Why?
| | Kaposi Varicelliform Eruption | 3 | 2011 | 21 | 0.200 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 19 | 0.200 |
Why?
| | Papillomavirus Infections | 2 | 2018 | 364 | 0.190 |
Why?
| | Heart Transplantation | 10 | 2001 | 714 | 0.190 |
Why?
| | Isoxazoles | 2 | 2013 | 54 | 0.190 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2013 | 3788 | 0.190 |
Why?
| | United States | 9 | 2024 | 15243 | 0.190 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.190 |
Why?
| | Lamivudine | 2 | 2015 | 63 | 0.190 |
Why?
| | Herpes Genitalis | 2 | 2012 | 18 | 0.190 |
Why?
| | HIV Integrase Inhibitors | 1 | 2023 | 72 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 66 | 0.190 |
Why?
| | Dendritic Cells | 1 | 2025 | 502 | 0.180 |
Why?
| | South Africa | 6 | 2020 | 199 | 0.180 |
Why?
| | Risk Factors | 18 | 2024 | 10482 | 0.180 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 25 | 0.180 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 96 | 0.180 |
Why?
| | Lymphocytosis | 1 | 2021 | 11 | 0.180 |
Why?
| | Genes, Viral | 1 | 2002 | 92 | 0.180 |
Why?
| | Central Nervous System Diseases | 1 | 2002 | 73 | 0.180 |
Why?
| | Antigens, Differentiation | 1 | 2001 | 83 | 0.180 |
Why?
| | Tuberculin Test | 1 | 2021 | 36 | 0.180 |
Why?
| | Biliary Atresia | 1 | 2023 | 153 | 0.180 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2002 | 224 | 0.180 |
Why?
| | Interferon-gamma Release Tests | 1 | 2021 | 33 | 0.180 |
Why?
| | Cells, Cultured | 11 | 2010 | 4205 | 0.170 |
Why?
| | Phenotype | 7 | 2009 | 3177 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2024 | 252 | 0.170 |
Why?
| | Maternal Exposure | 1 | 2023 | 201 | 0.170 |
Why?
| | Atazanavir Sulfate | 2 | 2023 | 42 | 0.170 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 75 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2021 | 78 | 0.170 |
Why?
| | Virus Activation | 3 | 2013 | 86 | 0.170 |
Why?
| | Immunoglobulins | 2 | 2017 | 167 | 0.170 |
Why?
| | Evolution, Molecular | 1 | 2005 | 506 | 0.170 |
Why?
| | North America | 2 | 2023 | 305 | 0.160 |
Why?
| | Receptors, Immunologic | 2 | 2000 | 215 | 0.160 |
Why?
| | Sensitivity and Specificity | 5 | 2009 | 1974 | 0.160 |
Why?
| | HIV Seronegativity | 1 | 2020 | 30 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2002 | 208 | 0.160 |
Why?
| | Virus Cultivation | 3 | 2005 | 31 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 546 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 567 | 0.150 |
Why?
| | Heart-Assist Devices | 8 | 2000 | 561 | 0.150 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 51 | 0.150 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.150 |
Why?
| | Treatment Outcome | 16 | 2017 | 11194 | 0.150 |
Why?
| | Inflammation | 4 | 2019 | 2895 | 0.150 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2017 | 13 | 0.150 |
Why?
| | Eicosanoids | 1 | 2019 | 63 | 0.150 |
Why?
| | Survival Analysis | 6 | 2018 | 1323 | 0.150 |
Why?
| | Abatacept | 2 | 2013 | 56 | 0.150 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2016 | 85 | 0.150 |
Why?
| | Cholera Toxin | 1 | 2018 | 31 | 0.150 |
Why?
| | Postoperative Complications | 14 | 2001 | 2824 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 694 | 0.140 |
Why?
| | Saliva | 2 | 2010 | 247 | 0.140 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 71 | 0.140 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 175 | 0.140 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 210 | 0.140 |
Why?
| | Latin America | 1 | 2018 | 89 | 0.140 |
Why?
| | Genotype | 6 | 2020 | 1865 | 0.140 |
Why?
| | Cell Movement | 2 | 2001 | 983 | 0.140 |
Why?
| | CD4-CD8 Ratio | 2 | 2008 | 24 | 0.130 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 12 | 0.130 |
Why?
| | Vaccination Coverage | 1 | 2018 | 98 | 0.130 |
Why?
| | Injections, Intradermal | 1 | 2017 | 12 | 0.130 |
Why?
| | Cell Line | 5 | 2009 | 2880 | 0.130 |
Why?
| | Coronary Artery Bypass | 4 | 2001 | 247 | 0.130 |
Why?
| | Injections, Subcutaneous | 2 | 2016 | 165 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2020 | 278 | 0.130 |
Why?
| | Paralysis | 1 | 2017 | 70 | 0.130 |
Why?
| | Arm | 1 | 2017 | 109 | 0.130 |
Why?
| | Seroconversion | 1 | 2017 | 45 | 0.130 |
Why?
| | Placenta | 2 | 2021 | 764 | 0.130 |
Why?
| | Africa | 1 | 2017 | 115 | 0.130 |
Why?
| | Kinetics | 3 | 2010 | 1654 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.120 |
Why?
| | Animals | 24 | 2011 | 37642 | 0.120 |
Why?
| | Seizures | 1 | 2020 | 439 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1036 | 0.120 |
Why?
| | Adoptive Transfer | 3 | 2002 | 223 | 0.120 |
Why?
| | Cross Reactions | 2 | 2014 | 133 | 0.120 |
Why?
| | Base Sequence | 6 | 2017 | 2172 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 768 | 0.120 |
Why?
| | Demography | 2 | 2018 | 296 | 0.120 |
Why?
| | Colorado | 2 | 2023 | 4599 | 0.120 |
Why?
| | Aging | 3 | 2017 | 1921 | 0.120 |
Why?
| | Comorbidity | 2 | 2019 | 1672 | 0.120 |
Why?
| | Nevirapine | 1 | 2015 | 18 | 0.120 |
Why?
| | RNA | 1 | 2022 | 930 | 0.120 |
Why?
| | Contraceptives, Oral, Synthetic | 1 | 2015 | 1 | 0.110 |
Why?
| | Nasopharynx | 1 | 2015 | 73 | 0.110 |
Why?
| | Nasal Lavage Fluid | 2 | 2005 | 15 | 0.110 |
Why?
| | Virus Latency | 2 | 2013 | 80 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | Immunoenzyme Techniques | 2 | 2006 | 208 | 0.110 |
Why?
| | Skin Diseases | 1 | 2016 | 148 | 0.110 |
Why?
| | Neutropenia | 1 | 2015 | 155 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1493 | 0.110 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 170 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1505 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 665 | 0.110 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 97 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1658 | 0.110 |
Why?
| | Graft Rejection | 5 | 2001 | 546 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 206 | 0.100 |
Why?
| | Herpesvirus 8, Human | 2 | 2005 | 66 | 0.100 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.100 |
Why?
| | Anemia | 1 | 2015 | 176 | 0.100 |
Why?
| | Feces | 1 | 2017 | 493 | 0.100 |
Why?
| | Progesterone | 2 | 2015 | 258 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2015 | 207 | 0.100 |
Why?
| | Leukocyte Common Antigens | 2 | 2009 | 90 | 0.100 |
Why?
| | Anesthesiology | 1 | 2016 | 170 | 0.100 |
Why?
| | Polyomavirus Infections | 1 | 2013 | 30 | 0.100 |
Why?
| | Epitopes | 2 | 2009 | 477 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2013 | 50 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 183 | 0.100 |
Why?
| | OX40 Ligand | 4 | 2001 | 10 | 0.100 |
Why?
| | Mothers | 1 | 2019 | 777 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 1010 | 0.100 |
Why?
| | Proctitis | 1 | 2012 | 7 | 0.090 |
Why?
| | Oxadiazoles | 1 | 2012 | 35 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1327 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2013 | 119 | 0.090 |
Why?
| | Rats, Inbred Lew | 4 | 1998 | 105 | 0.090 |
Why?
| | Aprotinin | 3 | 1997 | 9 | 0.090 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 3 | 0.090 |
Why?
| | DNA Primase | 1 | 2012 | 47 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 162 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1489 | 0.090 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 118 | 0.090 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2011 | 10 | 0.090 |
Why?
| | Viral Plaque Assay | 3 | 2006 | 34 | 0.090 |
Why?
| | L-Selectin | 2 | 2009 | 24 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 2 | 1990 | 65 | 0.090 |
Why?
| | Histocompatibility Testing | 3 | 2001 | 123 | 0.090 |
Why?
| | CD8 Antigens | 1 | 2011 | 76 | 0.090 |
Why?
| | Guanine | 3 | 2006 | 81 | 0.090 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.090 |
Why?
| | Ribavirin | 1 | 2011 | 82 | 0.080 |
Why?
| | DNA Helicases | 1 | 2012 | 142 | 0.080 |
Why?
| | Immunization Schedule | 3 | 2020 | 202 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2016 | 386 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 718 | 0.080 |
Why?
| | Parturition | 1 | 2011 | 67 | 0.080 |
Why?
| | Length of Stay | 3 | 2014 | 1267 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 2072 | 0.080 |
Why?
| | Logistic Models | 5 | 2010 | 2095 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Fetal Blood | 2 | 2019 | 336 | 0.080 |
Why?
| | Menstrual Cycle | 1 | 2011 | 134 | 0.080 |
Why?
| | Algorithms | 3 | 2021 | 1764 | 0.080 |
Why?
| | Herpes Simplex Virus Vaccines | 1 | 2009 | 4 | 0.080 |
Why?
| | Granzymes | 1 | 2009 | 50 | 0.080 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 7 | 0.080 |
Why?
| | Immune System | 2 | 2008 | 183 | 0.080 |
Why?
| | Human Experimentation | 1 | 2009 | 12 | 0.080 |
Why?
| | Neuralgia, Postherpetic | 1 | 2009 | 40 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2011 | 249 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 165 | 0.070 |
Why?
| | Plasma | 2 | 2018 | 222 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 193 | 0.070 |
Why?
| | Cost of Illness | 1 | 2011 | 311 | 0.070 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2008 | 16 | 0.070 |
Why?
| | Nasal Mucosa | 1 | 2009 | 111 | 0.070 |
Why?
| | Mice | 13 | 2011 | 18092 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1241 | 0.070 |
Why?
| | Inflammation Mediators | 1 | 2011 | 517 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 843 | 0.070 |
Why?
| | Botswana | 2 | 2019 | 9 | 0.070 |
Why?
| | Betaherpesvirinae | 1 | 2008 | 1 | 0.070 |
Why?
| | Infant Mortality | 2 | 2019 | 121 | 0.070 |
Why?
| | Genetic Variation | 2 | 2011 | 995 | 0.070 |
Why?
| | Exodeoxyribonucleases | 1 | 2008 | 23 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 91 | 0.070 |
Why?
| | Interleukin-15 | 1 | 2008 | 100 | 0.070 |
Why?
| | Cyclosporine | 2 | 2001 | 265 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2008 | 123 | 0.070 |
Why?
| | Sarcoma | 1 | 2010 | 193 | 0.070 |
Why?
| | Rats | 5 | 1998 | 5595 | 0.070 |
Why?
| | Trypan Blue | 1 | 2007 | 6 | 0.070 |
Why?
| | Didanosine | 1 | 2007 | 13 | 0.070 |
Why?
| | Thymus Gland | 1 | 2008 | 317 | 0.070 |
Why?
| | Gene Expression | 3 | 2006 | 1492 | 0.070 |
Why?
| | Quality Control | 1 | 2007 | 162 | 0.060 |
Why?
| | In Vitro Techniques | 3 | 2006 | 1095 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 375 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 289 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 91 | 0.060 |
Why?
| | Vero Cells | 1 | 2006 | 87 | 0.060 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 91 | 0.060 |
Why?
| | Pneumonia | 1 | 2013 | 656 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1605 | 0.060 |
Why?
| | Transfection | 3 | 2002 | 936 | 0.060 |
Why?
| | Veterans | 1 | 2018 | 1521 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 367 | 0.060 |
Why?
| | Drug Interactions | 2 | 2020 | 404 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 911 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2007 | 202 | 0.060 |
Why?
| | Opportunistic Infections | 2 | 2014 | 46 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 861 | 0.060 |
Why?
| | Hemostatics | 2 | 1997 | 58 | 0.060 |
Why?
| | Risk Assessment | 2 | 2014 | 3515 | 0.060 |
Why?
| | Hemadsorption | 1 | 2005 | 1 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4413 | 0.060 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2005 | 16 | 0.060 |
Why?
| | Tumor Necrosis Factors | 3 | 2001 | 10 | 0.060 |
Why?
| | Signal Transduction | 2 | 2000 | 5153 | 0.060 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 172 | 0.060 |
Why?
| | Gene Products, pol | 1 | 2005 | 6 | 0.060 |
Why?
| | Annexin A5 | 1 | 2004 | 26 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2017 | 77 | 0.060 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2004 | 50 | 0.060 |
Why?
| | Antigens | 2 | 2008 | 361 | 0.060 |
Why?
| | Meningitis, Viral | 1 | 2004 | 20 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2026 | 168 | 0.050 |
Why?
| | Measles virus | 1 | 2024 | 20 | 0.050 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2004 | 5 | 0.050 |
Why?
| | Sarcoma, Kaposi | 2 | 2003 | 80 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2002 | 416 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 70 | 0.050 |
Why?
| | Adenoviruses, Human | 1 | 2004 | 27 | 0.050 |
Why?
| | Emtricitabine | 2 | 2021 | 204 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 368 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2005 | 308 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.050 |
Why?
| | Measles | 1 | 2024 | 48 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 2001 | 359 | 0.050 |
Why?
| | Survival Rate | 8 | 2001 | 1973 | 0.050 |
Why?
| | HLA-DR Antigens | 3 | 2001 | 227 | 0.050 |
Why?
| | Rilpivirine | 1 | 2023 | 9 | 0.050 |
Why?
| | Hospital Mortality | 4 | 2001 | 929 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 83 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2023 | 42 | 0.050 |
Why?
| | Bronchiolitis Obliterans | 2 | 2001 | 65 | 0.050 |
Why?
| | Darunavir | 1 | 2023 | 19 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3504 | 0.050 |
Why?
| | Herpes Labialis | 1 | 2003 | 8 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2010 | 655 | 0.050 |
Why?
| | DNA Primers | 3 | 2009 | 508 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Pregnancy Trimester, First | 1 | 2023 | 136 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 335 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 649 | 0.050 |
Why?
| | Risk | 1 | 2005 | 904 | 0.050 |
Why?
| | Parapsychology | 1 | 2001 | 1 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 200 | 0.050 |
Why?
| | Electromagnetic Fields | 1 | 2001 | 38 | 0.050 |
Why?
| | Zimbabwe | 2 | 2017 | 61 | 0.050 |
Why?
| | B7-1 Antigen | 2 | 1998 | 57 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2003 | 367 | 0.040 |
Why?
| | Ovalbumin | 1 | 2001 | 196 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 1994 | 2919 | 0.040 |
Why?
| | Cobicistat | 1 | 2021 | 5 | 0.040 |
Why?
| | Receptors, CXCR5 | 1 | 2021 | 23 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2001 | 102 | 0.040 |
Why?
| | Rituximab | 2 | 2013 | 205 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2021 | 60 | 0.040 |
Why?
| | Photography | 1 | 2001 | 115 | 0.040 |
Why?
| | Liver Diseases | 1 | 2024 | 302 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 50 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2002 | 129 | 0.040 |
Why?
| | Lymphoma | 1 | 2002 | 229 | 0.040 |
Why?
| | Prostheses and Implants | 3 | 1996 | 143 | 0.040 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2020 | 7 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2020 | 10 | 0.040 |
Why?
| | Models, Statistical | 1 | 2005 | 670 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 33 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1990 | 2608 | 0.040 |
Why?
| | Pre-Eclampsia | 1 | 2023 | 200 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2016 | 1314 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2001 | 115 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 269 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2020 | 116 | 0.040 |
Why?
| | Glioma | 1 | 2005 | 418 | 0.040 |
Why?
| | DNA | 2 | 2006 | 1441 | 0.040 |
Why?
| | Surface Properties | 1 | 2001 | 414 | 0.040 |
Why?
| | Spinal Cord | 2 | 1994 | 375 | 0.040 |
Why?
| | Heart Failure | 3 | 1999 | 2118 | 0.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2002 | 168 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 158 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 326 | 0.040 |
Why?
| | Trans-Activators | 1 | 2002 | 394 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 31 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2001 | 166 | 0.040 |
Why?
| | Hemodynamics | 3 | 2001 | 1100 | 0.040 |
Why?
| | Coronary Disease | 2 | 2001 | 372 | 0.040 |
Why?
| | Interleukin-3 | 3 | 1994 | 24 | 0.040 |
Why?
| | Antibodies | 1 | 2001 | 411 | 0.040 |
Why?
| | Prognosis | 3 | 2024 | 4077 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2019 | 106 | 0.040 |
Why?
| | California | 2 | 2015 | 457 | 0.040 |
Why?
| | Candidiasis | 1 | 1999 | 62 | 0.040 |
Why?
| | Triiodothyronine | 1 | 1999 | 50 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 673 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 70 | 0.040 |
Why?
| | Hemagglutination | 1 | 2018 | 8 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 28 | 0.040 |
Why?
| | Tenofovir | 1 | 2021 | 283 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5651 | 0.040 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2000 | 117 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 1998 | 43 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2132 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1271 | 0.040 |
Why?
| | Brain Diseases | 1 | 2020 | 149 | 0.040 |
Why?
| | Neoplasms | 3 | 2001 | 2731 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1815 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 331 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 56 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 60 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 1998 | 136 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1812 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1998 | 187 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2019 | 162 | 0.030 |
Why?
| | Protein Precursors | 1 | 2018 | 134 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 53 | 0.030 |
Why?
| | Shock | 1 | 1998 | 104 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 22 | 0.030 |
Why?
| | Sterols | 1 | 2017 | 20 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 405 | 0.030 |
Why?
| | Autogenic Training | 1 | 1997 | 1 | 0.030 |
Why?
| | Proviruses | 1 | 2017 | 16 | 0.030 |
Why?
| | Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1997 | 4 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 68 | 0.030 |
Why?
| | Radioactive Hazard Release | 1 | 1997 | 3 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 119 | 0.030 |
Why?
| | Sequence Analysis | 1 | 2017 | 36 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 52 | 0.030 |
Why?
| | Power Plants | 1 | 1997 | 9 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 57 | 0.030 |
Why?
| | Relaxation Therapy | 1 | 1997 | 19 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3343 | 0.030 |
Why?
| | Encephalitis | 1 | 1998 | 137 | 0.030 |
Why?
| | Lung Injury | 1 | 2000 | 227 | 0.030 |
Why?
| | Ligands | 1 | 1999 | 667 | 0.030 |
Why?
| | Heart Valves | 1 | 1997 | 42 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1996 | 44 | 0.030 |
Why?
| | Prevalence | 2 | 2018 | 2793 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 25 | 0.030 |
Why?
| | Erythema | 1 | 2016 | 28 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1997 | 98 | 0.030 |
Why?
| | Body Weight | 1 | 2020 | 996 | 0.030 |
Why?
| | Up-Regulation | 2 | 2001 | 856 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 2016 | 24 | 0.030 |
Why?
| | Heart Arrest, Induced | 1 | 1995 | 34 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1998 | 256 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 523 | 0.030 |
Why?
| | Thromboembolism | 1 | 1996 | 127 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 355 | 0.030 |
Why?
| | Vasodilation | 1 | 1998 | 517 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2016 | 290 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 805 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1483 | 0.030 |
Why?
| | Blood Transfusion | 2 | 1995 | 393 | 0.030 |
Why?
| | Interleukin-4 | 2 | 1998 | 215 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2177 | 0.030 |
Why?
| | Ovulation | 1 | 2015 | 40 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1817 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2001 | 1472 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 311 | 0.030 |
Why?
| | Cross Infection | 1 | 1997 | 253 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 1997 | 159 | 0.030 |
Why?
| | Hypothermia, Induced | 1 | 1995 | 92 | 0.030 |
Why?
| | Rats, Inbred BUF | 1 | 1994 | 1 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 1995 | 112 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 48 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1997 | 321 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1994 | 80 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 2003 | 68 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1996 | 312 | 0.030 |
Why?
| | Quality of Life | 4 | 2000 | 3021 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2001 | 1074 | 0.030 |
Why?
| | Colony-Stimulating Factors | 2 | 1990 | 37 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 577 | 0.030 |
Why?
| | Aortic Valve | 1 | 1996 | 359 | 0.020 |
Why?
| | Cause of Death | 3 | 2001 | 446 | 0.020 |
Why?
| | BK Virus | 1 | 2013 | 16 | 0.020 |
Why?
| | Growth Substances | 2 | 1990 | 144 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 290 | 0.020 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 22 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 1990 | 412 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2007 | 773 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2373 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1998 | 587 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1990 | 159 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1992 | 30 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2001 | 1280 | 0.020 |
Why?
| | Heart Diseases | 1 | 1995 | 335 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 1794 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 1995 | 517 | 0.020 |
Why?
| | Spleen | 1 | 1994 | 522 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 912 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1996 | 587 | 0.020 |
Why?
| | Patient Selection | 1 | 1995 | 685 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 786 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 702 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1992 | 108 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 1012 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 38 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 52 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 534 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1997 | 600 | 0.020 |
Why?
| | Stroke | 1 | 2000 | 1195 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 824 | 0.020 |
Why?
| | Radiotherapy | 2 | 2005 | 203 | 0.020 |
Why?
| | Cattle | 2 | 1990 | 991 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 2001 | 2555 | 0.020 |
Why?
| | Polyribosomes | 1 | 1990 | 24 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 317 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1990 | 154 | 0.020 |
Why?
| | Concanavalin A | 1 | 1990 | 73 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1990 | 156 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1990 | 92 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 199 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 499 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2010 | 121 | 0.020 |
Why?
| | Infant, Premature | 1 | 2014 | 598 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2011 | 375 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1543 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 3065 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 793 | 0.020 |
Why?
| | Herpesvirus 1, Bovine | 1 | 1989 | 3 | 0.020 |
Why?
| | Anxiety | 1 | 1997 | 1078 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 656 | 0.020 |
Why?
| | Ribosomes | 1 | 1990 | 186 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 758 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2010 | 331 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 411 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1998 | 1179 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 185 | 0.020 |
Why?
| | Phylogeny | 1 | 2013 | 1005 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1994 | 468 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 855 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 1999 | 417 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1197 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1994 | 1157 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1990 | 444 | 0.020 |
Why?
| | Time | 1 | 2007 | 87 | 0.020 |
Why?
| | Drug Resistance, Multiple | 1 | 2006 | 25 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 678 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2163 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2007 | 271 | 0.010 |
Why?
| | Templates, Genetic | 1 | 2005 | 63 | 0.010 |
Why?
| | Cell Differentiation | 4 | 2000 | 2001 | 0.010 |
Why?
| | Postoperative Care | 2 | 1999 | 280 | 0.010 |
Why?
| | Internship and Residency | 1 | 2016 | 1225 | 0.010 |
Why?
| | Codon | 1 | 2005 | 92 | 0.010 |
Why?
| | Interleukin-5 | 2 | 1998 | 42 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1493 | 0.010 |
Why?
| | DNA Replication | 1 | 2006 | 239 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 2000 | 2178 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 397 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 381 | 0.010 |
Why?
| | Creatinine | 2 | 1997 | 491 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 405 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 47 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4129 | 0.010 |
Why?
| | Endemic Diseases | 1 | 2003 | 35 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2798 | 0.010 |
Why?
| | Peptide Fragments | 2 | 1998 | 699 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2003 | 162 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 817 | 0.010 |
Why?
| | Bioelectric Energy Sources | 1 | 2001 | 4 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2001 | 22 | 0.010 |
Why?
| | Electricity | 1 | 2001 | 25 | 0.010 |
Why?
| | Galvanic Skin Response | 1 | 2001 | 25 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2001 | 86 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2001 | 22 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2001 | 201 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 2001 | 111 | 0.010 |
Why?
| | Fingers | 1 | 2001 | 106 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2001 | 57 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2001 | 75 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2001 | 432 | 0.010 |
Why?
| | Anticoagulants | 2 | 1996 | 725 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 445 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 84 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 2153 | 0.010 |
Why?
| | Probability | 1 | 2001 | 308 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2001 | 5901 | 0.010 |
Why?
| | Clone Cells | 1 | 2000 | 268 | 0.010 |
Why?
| | Databases as Topic | 1 | 2000 | 68 | 0.010 |
Why?
| | Emergency Treatment | 1 | 2001 | 125 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 210 | 0.010 |
Why?
| | New York | 1 | 2000 | 128 | 0.010 |
Why?
| | Carotid Artery Diseases | 1 | 2000 | 62 | 0.010 |
Why?
| | Students | 1 | 2005 | 645 | 0.010 |
Why?
| | Peripheral Vascular Diseases | 1 | 2000 | 104 | 0.010 |
Why?
| | Columbidae | 1 | 1998 | 31 | 0.010 |
Why?
| | Cytochrome c Group | 1 | 1998 | 44 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 1999 | 95 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2001 | 500 | 0.010 |
Why?
| | Cardiac Output | 1 | 1999 | 177 | 0.010 |
Why?
| | Life Tables | 1 | 1998 | 20 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 672 | 0.010 |
Why?
| | Endocardium | 1 | 1998 | 31 | 0.010 |
Why?
| | Aortic Diseases | 1 | 2000 | 119 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1999 | 364 | 0.010 |
Why?
| | Calcinosis | 1 | 2000 | 238 | 0.010 |
Why?
| | Hypotension | 1 | 1998 | 122 | 0.010 |
Why?
| | Cell Death | 1 | 1999 | 388 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2000 | 169 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 197 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 217 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1760 | 0.010 |
Why?
| | Ukraine | 1 | 1997 | 22 | 0.010 |
Why?
| | Endocarditis, Bacterial | 1 | 1997 | 46 | 0.010 |
Why?
| | Odds Ratio | 1 | 2000 | 1057 | 0.010 |
Why?
| | Models, Structural | 1 | 1996 | 41 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2061 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1996 | 46 | 0.010 |
Why?
| | Radiometry | 1 | 1997 | 54 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1998 | 369 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1997 | 94 | 0.010 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 1996 | 44 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1996 | 46 | 0.010 |
Why?
| | Health Care Costs | 1 | 2000 | 418 | 0.010 |
Why?
| | Equipment Failure | 1 | 1996 | 111 | 0.010 |
Why?
| | Urogenital Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
| | Europe | 1 | 1997 | 407 | 0.010 |
Why?
| | Vital Capacity | 1 | 1996 | 306 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 2001 | 375 | 0.010 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 100 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 1996 | 198 | 0.010 |
Why?
| | Blood Urea Nitrogen | 1 | 1995 | 54 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 1997 | 120 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 1996 | 484 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 1012 | 0.010 |
Why?
| | Aortic Aneurysm | 1 | 1995 | 70 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 835 | 0.010 |
Why?
| | Child Development | 1 | 2000 | 496 | 0.010 |
Why?
| | Hodgkin Disease | 1 | 1997 | 157 | 0.010 |
Why?
| | Equipment Design | 1 | 1996 | 527 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1070 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 1269 | 0.010 |
Why?
| | Waiting Lists | 1 | 1996 | 245 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1998 | 719 | 0.010 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1994 | 45 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 841 | 0.010 |
Why?
| | Reoperation | 1 | 1997 | 593 | 0.010 |
Why?
| | Exercise Test | 1 | 1996 | 623 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1994 | 470 | 0.010 |
Why?
| | Myocardium | 1 | 1998 | 927 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1997 | 321 | 0.010 |
Why?
| | Ventricular Function, Right | 1 | 1995 | 283 | 0.010 |
Why?
| | Central Nervous System | 1 | 1994 | 264 | 0.010 |
Why?
| | Patient Compliance | 1 | 1997 | 608 | 0.010 |
Why?
| | Smoking | 1 | 2000 | 1573 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 1025 | 0.010 |
Why?
| | Blood Pressure | 1 | 1998 | 1747 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2000 | 1076 | 0.010 |
Why?
| | Head and Neck Neoplasms | 1 | 1995 | 555 | 0.010 |
Why?
| | Research Design | 1 | 1997 | 1105 | 0.010 |
Why?
| | Lymphocyte Cooperation | 1 | 1990 | 49 | 0.010 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.010 |
Why?
| | Thymectomy | 1 | 1990 | 15 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 1990 | 59 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1990 | 157 | 0.000 |
Why?
| | Infectious Bovine Rhinotracheitis | 1 | 1989 | 1 | 0.000 |
Why?
| | Phorbol Esters | 1 | 1989 | 14 | 0.000 |
Why?
| | Ionomycin | 1 | 1989 | 22 | 0.000 |
Why?
| | Rabbits | 1 | 1990 | 754 | 0.000 |
Why?
| | Ethers | 1 | 1989 | 19 | 0.000 |
Why?
| | Immunotherapy | 1 | 1994 | 644 | 0.000 |
Why?
| | Kidney | 1 | 1997 | 1482 | 0.000 |
Why?
| | Isoantigens | 1 | 1988 | 17 | 0.000 |
Why?
| | Cell-Free System | 1 | 1988 | 55 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 2000 | 5937 | 0.000 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2247 | 0.000 |
Why?
| | Models, Biological | 1 | 1988 | 1826 | 0.000 |
Why?
|
|
Weinberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|